About the Company
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon sells to international markets.
NEW YORK STOCK EXCHANGE INC.
|Name||Ticker||Market Capitalization (USD M)||Revenue (USD M)||Price/Book||Price/Earning||Net Margin (%)|
|Conversion Labs Inc||CVLB||108548||35213||3.74||42.66||7.33|
|Royalty Pharma plc||RPRX||19327||2239||2.87||15.52||43.40|
|Organon & Co.||OGN||8644||7891||-4.46||4.95||22.06|
|ATAI Life Sciences N.V.||ATAI||2545||20||5.35||-11.65||-932.88|
|Cronos Group Inc||CRON||2114||57||1.33||-14.64||-258.59|
|Usana Health Sciences Inc||USNA||1837||1254||4.18||13.23||11.09|
|Phathom Pharmaceuticals Inc||PHAT||1178||7.99||-7.35||None|
|Fulcrum Therapeutics Inc||FULC||925||15||11.21||-12.53||-481.07|
|Intersect ENT Inc||XENT||899||103||21.80||-13.10||-66.55|
|Phibro Animal Health Corp.||PAHC||888||833||3.68||16.16||6.53|
|Edgewise Therapeutics Inc||EWTX||848||2.87||-31.45||None|
|Pliant Therapeutics Inc||PLRX||657||13||2.69||-7.66||-613.56|
|Cyteir Therapeutics Inc||CYT||637||3.42||-22.04||None|
|Urovant Sciences Ltd||UROV||503||-3.65||-3.08||None|
|Ikena Oncology Inc||IKNA||467||10||2.52||-8.53||-551.28|
|Rain Therapeutics Inc||RAIN||404||413||2.50||-13.27||123.20|
|Provention Bio Inc||PRVB||400||2.68||-3.12||None|
|Verrica Pharmaceuticals Inc||VRCA||316||12||6.41||-8.69||-301.45|
|Terns Pharmaceuticals Inc||TERN||263||1.46||-7.62||None|
|Adicet Bio Inc||ACET||230||9||1.00||-4.09||-603.06|
|Milestone Pharmaceuticals Inc||MIST||222||15||1.25||-7.50||-215.93|
|Kaleido Biosciences Inc||KLDO||222||1||4.94||-2.49||None|
|Kala Pharmaceuticals Inc||KALA||187||11||2.42||-1.48||None|
|Osmotica Pharmaceuticals Plc||OSMT||181||190||2.64||-1.95||-47.85|
|Citius Pharmaceuticals Inc||CTXR||177||2.21||-7.70||None|
|Aquestive Therapeutics Inc||AQST||146||42||-3.02||-2.27||-152.73|
|Eton Pharmaceuticals Inc||ETON||123||15||6.11||-10.06||-74.52|
|Odonate Therapeutics Inc||ODT||117||1.47||-1.00||None|
|Aerpio Pharmaceuticals Inc||ARPO||99||15||2.98||-5.24||-28.77|
|Opiant Pharmaceuticals Inc||OPNT||90||37||2.71||-86.08||-3.06|
|Natural Alternatives Internati||NAII||89||169||1.26||10.07||5.68|
|VYNE Therapeutics Inc||VYNE||72||16||1.08||3.27||-554.66|
|India Globalization Capital In||IGC||67||0||2.39||-7.65||-981.18|
|Acasti Pharma Inc||ACST||42||0||1.81||-2.11||-611.47|
|Assertio Holdings Inc||ASRT||33||117||0.45||-0.58||-38.05|
|Reviva Pharmaceuticals Holding||RVPH||30||1.64||-4.74||None|
|Baudax Bio Inc||BXRX||28||1||-11.98||0.84||None|
|Nabriva Therapeutics Plc||NBRV||28||12||0.83||-0.47||-452.55|
|Bio-Path Holdings Inc||BPTH||28||0||1.29||-2.68||18.96|
|Timber Pharmaceuticals Inc||TMBR||26||0||11.39||0.88||-527.55|
|Trevi Therapeutics Inc||TRVI||26||1.67||-0.74||None|
|Lexaria Bioscience Corp||LEXX||25||1||3.49||-6.45||-445.15|
|Hoth Therapeutics Inc||HOTH||22||1.85||-2.29||None|
|Sonoma Pharmaceuticals Inc.||SNOA||11||17||3.13||-2.04||-31.96|
Investment company Blackrock Funds (Current Portfolio) buys Organon during the 3-months ended 2021Q2, according to the most recent filings of the investment company, Blackrock Funds.
Organon has touched ground in a few areas, including therapeutics and disease areas, but is looking to expand its portfolio based on women’s needs both throughout their lifetime and in areas ...
JERSEY CITY, N.J., September 01, 2021--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to ...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a ...
These 6 analysts have an average price target of $36.5 versus the current price of Organon at 35.155, implying upside. Below is a summary of how these 6 analysts rated Organon over the past 3 months.
Aristotle's Modal Logic, first published in 1995, presents an interpretation of Aristotle's logic by arguing that a proper understanding of the system depends on an appreciation of its connection to ...
The company, originally called InPress Technologies and now Alydia Health, sold this month to the Merck-spinoff company Organon for $240 million. Cal Poly students and a team of San Luis Obispo ...
Merck & Co., Inc. (MRK) CEO Robert Davis Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
We feel very good about where we are. We've completed the Organon spin-off. We made it through that with really no disruptions or surprises. And in fact, both Organon and Merck are operating at or ...
The team later advised Merck on the tax issues concerning Euro-and dollar-denominated secured and unsecured debt financing in connection with the spinoff of Organon, a global health care company.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fire ...
Looking for an examination copy? This title is not currently available for examination. However, if you are interested in the title for your course we can consider offering an examination copy. To ...